tiprankstipranks
Biogen price target raised to $350 from $335 at RBC Capital
The Fly

Biogen price target raised to $350 from $335 at RBC Capital

RBC Capital analyst Brian Abrahams raised the firm’s price target on Biogen to $350 from $335 and keeps an Outperform rating on the shares. The firm’s recently conducted proprietary physician survey on perceptions of zuranolone ahead of the upcoming launch has left the analyst with greater confidence that physicians are appreciating its differentiated mechanism of action and rapidity of onset, RBC tells investors in a research note. The firm models $1.9B/$200M peak end-user sales potential in MDD/PPD while also increasing its probability of success estimate to 75%.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on BIIB:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles